The molecular genetics of pancreatic ductal carcinoma: A review

Surgical Oncology

Volumn 9, Issue 3, 2000, Pages 95-101

  Sohn, T A ^a   Yeo, C J ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; BRCA2 PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PROTEIN P16; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CANCER GENETICS; CAUSE OF DEATH; HUMAN; MOLECULAR GENETICS; ONCOGENE K RAS; PANCREAS ADENOCARCINOMA; PANCREAS DUCT; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; UNITED STATES;

EID: 0034445896     PISSN: 09607404     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-7404(00)00041-4     Document Type: Short Survey

References (68)

1. Hruban RH, Peterson GM, Ha PK, et al. Genetics of pancreatic cancer: from genes to families. Surgical Oncology Clinics of North America 1998;7:1-23.
2. Lengauer C., Kinzler K.W., Vogelstein B. Genetic instability in colorectal cancers. Nature. 386:1997;623-627.
3. Lengauer C., Kinzler K.W., Vogelstein B. Genetic instabilities in human cancers. Nature. 396:1998;643-649.
4. Rozenblum E, Schutte M, Goggins M, et al. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Research 1997;57:1731-4.
5. Almoguerra C, Shibata D, Forrester K, et al. Most human carcinomas of the exocrine pancreas contain mutant c-k-ras genes. Cell 1988;53:549-54.
6. Hahn SA, Schutte M, Hoque ATMS, et al. DPC4, a candidate tumor-suppressor gene at 18q21.1. Science 1996;271:350-3.
7. Wilentz RE, Iacobuzio-Donahue CA, Aragani P, et al. Loss of expression of DPC4 in pancreatic intrapithelial neoplasia (PanIN): evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Research 2000;60:2002-6.
8. Hruban RH, van Mansfeld ADM, Offerhaus GJA, et al. k-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. American Journal of Pathology 1993;143:545-54.
9. Wilentz RE, Goggins M, Redston M, et al. Genetics, immunohistochemical, and clinical features of medullary carcinoma of the pancreas: a newly described and characterized entity. American Journal of Pathology 2000;156:1641-51.
10. Goggins M, Offerhaus GJA, Hilgers W, et al. Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type k-ras and characteristic histopathology: poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+. American Journal of Pathology 1998;152:1501-7.
11. Wilentz RE, Chung CH, Sturm PDJ, et al. k-ras mutations in duodenal fluid of patients with pancreas carcinoma. Cancer 1998;82:96-103.
12. Berthelemy P, Bouisson M, Escourrou J, et al. Identification of K-ras mutations in pancreatic juice early in the diagnosis of pancreatic cancer. Annals of Internal Medicine 1995;123:188-91.
13. Caldas C, Hahn SA, Hruban RH, et al. Detection of k-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal mucinous cell hyperplasia. Cancer Research 1994;54:3568-73.
14. Korinek V, Barker N, Morin PJ, et al. Consitutive transcriptional activation by a beta-catenin-Tcf complex in APC -/- colon carcinoma. Science 1997;275:1784-7.
15. He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science 1998;281:1509-12.
16. He TC, Chan TA, Vogelstein B, et al. PPARdelta is an APC regulated target of non-steroidal anti-inflammatory drugs. Cell 1999;99:335-45.
17. Morin PJ, Sparks AB, Korinek V, et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997;275:1787-90.
18. Caca K, Kolligs FT, Ju X, et al. Beta- and gamma-catenin mutations, but not E-cadherin inactivation, underlie T-cell factor/lymphoid enhancer factor transcriptional deregulation in gastric and pancreatic cancer. Cell Growth Differentiation 1999;10:369-76.
19. Seymour AB, Hruban RH, Redston M, et al. Allelotype of pancreatic adenocarcinoma. Cancer Research 1994;54:2761-4.
20. McKie AB, Filipe MI, Lemoine NR. Abnormalities affecting the APC and MCC tumour suppressor gene loci on chromosome 5q occur frequently in gastric cancer, but not pancreatic cancer. International Journal of Cancer 1993;55:598-603.
21. Yashima K, Nakamori S, Murakami Y, et al. Mutations of the adenomatous polyposis coli gene in the mutation cluster region: comparison of human pancreatic and colorectal cancers. International Journal of Cancer 1994;59:43-7.
22. Gerdes B, Ramaswamy A, Simon B, et al. Analysis of beta-catenin gene mutations in pancreatic tumours. Digestion 1999;60:544-8.
23. Nishita M, Hashimoto MK, Ogata S, et al. Interaction between Wnt and TGF-beta signaling pathways during formation of Spemann's Organizer. Nature 2000;403:781-5.
24. Cheng JQ, Ruggeri B, Klein WM, et al. Amplification of AKT2 in human pancreatic cancer cells and inhibition of AKT2 expression and tumorigenecity by antisense RNA. Proceedings of the National Academy of Science USA 1996;93:3636-41.
25. Ruggeri BA, Huang L, Wood M, et al. Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Molecular Carcinogenesis 1998;21:81-6.
26. Wallrapp C, Muller-Pillasch F, Solinas-Toldo S, et al. Characterization of a high copy number amplification of 6q24 in pancreatic cancer identifies c-myb as a candidate oncogene. Cancer Research 1997;57:3135-9.
27. Caldas C, Hahn SA, da Costa LT, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nature Genetics 1994;8:27-32.
28. Schutte M, Hruban RH, Geradts J, et al. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Research 1997;57:3126-30.
29. Moskaluk C.A., Hruban R.H., Kern S.E. p16 and k-ras mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Research. 57:1997;2140-2143.
30. INK4 allele (Asp145Cys) in a family with multiple pancreatic carcinomas. Human Mutatation 1998,12:70.
31. Lal G, Lui G, Schmocker B, et al. Inherited predisposition to pancreatic adenocaricnoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations. Cancer Research 2000;60:409-16.
32. Rugerri B, Zhang SY, Caamano J, et al. Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in the p53 and Rb-1 tumor-suppressor genes. Oncogene 1992;7:1503-11.
33. Ceha HM, Clement MJ, Polak M, et al. Mutaional analysis of the p16-binding domain of cylin-dependent kinase 4 in tumors in the head region of the pancreas. Pancreas 1998;17:85-8.
34. Polyak K, Xia Y, Zweier JL, et al. Identification and classification of p53-regulated genes. Proceedings of the National Academy of Science USA 1999;96:14517-22.
35. Hermeking H., Lengauer C., Polyak K.et al. 14-3-3 sigma is a p-53 regulated inhibitor of G2/M progression. Molecular Cell. 1:1997;3-11.
36. Wilentz RE, Su GH, Dai JL, et al. Immunohistochemical labeling for dpc4 mirrors genteic status in pancreatic adenocarcinomas: a new marker for DPC4 inactivation. American Journal of Pathology 2000;156:37-43.
37. Zawel L, Dai JL, Buckhaults P, et al. Human Smad3 and Smad4 are sequence specific transcription activators. Molecular Cell 1998;1:611-7.
38. Dai JL, Turnacioglu K, Schutte M, et al. Dpc4 transcriptional activation and dysfunction in cancer cells. Cancer Research 1998;58:4592-7.
39. Zhang Y, Feng X, We R, et al. Receptor-associated Mad homologues synergize as effectors of the TGF-beta response. Nature 1996;383:168-72.
40. Lagna G, Hata A, Hammati-Brivanlou A, et al. Partnership between DPC4 and SMAD proteins in TGF-beta signaling pathways. Nature 1996;383:832-6.
41. de Caestecker MP, Yahata T, Wang D, et al. The Smad4 activation domain (SAD) is a proline-rich, p300 dependent transcriptional activation domain. Journal of Biological Chemistry 2000;275:2115-22.
42. Zhou S, Zawel L, Lengauer C, et al. Characterization of human FAST-1, a TGF-beta and activin signal transducer. Molecular Cell 1998;2:121-127.
43. Hanafusa H, Ninomiya-Tsuji J, Masuyama N, et al. Involvement for the p38 mitogen-activated protein kinase pathway in transforming growth factor-beta-induced gene expression. Journal of Biological Chemistry 1999;274:27161-67.
44. Wotton D, Lo RS, Lee S, et al. A Smad transcriptional corepressor. Cell 1999;97:29-39.
45. Wotton D, Lo RS, Swaby LA, et al. Multiple modes of repression by the Smad transcriptional corepressor TGIF. Journal of Biological Chemistry 1999;274:37105-10.
46. Luo K, Stroschein SL, Wang W, et al. The Ski oncoprotein nteracts with the Smad proteins to repress TGF-beta signaling. Genes and Development 1999;13:2196-206.
47. Stroschein SL, Wang W, Zhou S, et al. Negative feedback regulation of TGF-beta signaling pathway by the SnoN oncoprotein. Science 1999;286:771-4.
48. Sun Y, Lui X, Eaton EN, et al. Interaction of the Ski oncoprotein with Smad3 regulates TGF-beta signaling. Molecular Cell 1999;4:499-509.
49. Engel ME, McDonnell MA, Law BK, et al. Interdependent SMAD and JNK signaling in transforming growth factor-beta-mediated transcription. Journal of Biological Chemistry 1999;274:37413-20.
50. Hocevar B.A., Brown T.L., Howe P.H. TGF-beta induces fibronectin synthesis through a c-Jun N-terminal kinase-dependent, Smad4-independent pathway. EMBO. 18:1999;1345-1356.
51. Dai JL, Schutte M, Bansal RK, et al. Transforming growth factor-beta responsiveness in DPC4/SMAD4-null cancer cells. Molecular Carcinogenesis 1999;26:37-43.
52. Sirard C, Kim S, Mirtsos, C, et al. Targeted disruption in murine cells reveals variable requirement for Smad4 in transforming growth factor-beta related signaling. Journal of Biological Chemistry 2000;275:2063-70.
53. Baldwin RL, Freiss H, Yokoyama M, et al. Attenuated ALK5 receptor expression in human pancreatic cancer: correlation with resistance to growth inhibition. International Journal of Cancer 1996;67:283-8.
54. Goggins M, Shekher M, Turnacioglu K, et al. Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas. Cancer Research 1998;58:5329-32.
55. Lu SL, Kawabata M, Imamura T, et al. HNPCC associated with germline mutations in the TGF-beta type II receptor gene. Nature Genetics 1998;19:17-8.
56. Teng DHF, Perry III, WL, Hogan JK, et al. Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor. Cancer Research 1997;57:4177-82.
57. Su GH, Hilgers W, Shekher MC, et al. Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene. Cancer Research 1998;58:2339-42.
58. Collins SP, Reoma JL, Gamm DM, et al. LKB1, a novel serine-threonine protein kinase and potential tumour suppressor, is phosphorylated by cAMP-dependent protein kinase (PKA) and prenylated in vivo. Biochemical Journal 2000;345:673-80.
59. Tiainen M., Ylikorkala A., Makela T.P. Growth suppression by Lkb1 is mediated by a G(1) cell cycle arrest. Proceedings of the National Academy of Science USA. 96:1999;9248-9251.
60. Su GH, Hruban RH, Bansal RK, et al. Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. American Journal of Pathology 1999;154:1835-1884.
61. Giardello FM, Welsh SB, Hamilton SR, et al. Increase risk of cancer in the Peutz-Jeghers syndrome. New England Journal of Medicine 1987; 316:1511-4.
62. Ozkelik H, Schmocker B, Di Nicola N, et al. Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients. Nature Genetics 1997;16:17-8.
63. Goggins M, Schutte M, Lu J, et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Research 1996;56:5360-4.
64. Goggins M., Hruban R.H., Kern S.E. BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia. evidence and implications American Journal of Pathology. 156:2000;1767-1771.
65. Lumadue JA, Grffin CA, Osman M, et al. Familial pancreatic cancer and the genetics of pancreatic cancer. Surgical Clinics of North America 1995;75:845-855.
66. Su GH, Kern SE. Molecular genetics of pancreatic ductal neoplasia. Current Opinions in Gastroenterology, in press.
67. Tersmette AC, Peterson GM, Offerhaus GJA, et al. Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer, submitted.
68. Su G.H., Sohn T.A., Ryu B., Dai J., Kern S.E. Depression of engineered reporter constructs by a novel inhibitor of histone deacetylase identified by high-throughput drug screening. Cancer Research. 60:2000;3137-3142.